Cellebrite DI Ltd. (CLBT) shares sold off after Q2 2026 annual recurring revenue of approximately $507.8 million came in below analyst consensus and the Company's own guidance; Cellebrite lowered its full year outlook in accord; Levi & Korsinsky is investigating.
Cellebrite DI Ltd. shares dropped over 30% after the Company reported Q2 2026 revenue of approximately $131.1 million and cut its full-year 2026 ARR and revenue guidance -- SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of CLBT investors who lost money.
Cellebrite DI Ltd. (CLBT) shareholders lost money when the stock sold off more than 30% following the Company's Q2 2026 results -- Levi & Korsinsky is investigating the Company's disclosures concerning their previous projections and related discussions.
MILWAUKEE, Aug. 13, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Cellebrite (NASDAQ: CLBT). The investigation results from inaccurate statements Cellebrite may have made regarding its financial statements, business operations and prospects.
TYSONS CORNER, Va. and PETAH TIKVA, Israel, July 21, 2026 /PRNewswire/ -- Cellebrite DI Ltd. (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced it will report its second-quarter 2026 financial results before the U.S. markets open on Thursday, August 13, 2026.
TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 5, 2026 /PRNewswire/ -- Cellebrite DI Ltd. (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced that the Company plans to participate in two upcoming investor events on June 10, 2026.